Anti-AP2 antibodies and antigen binding agents to treat metabolic disorders
This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as "aP2") for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | WIDENMAIER, SCOTT B WALES, SHAUNA MHAIRI ADAMS, RALPH ENGIN, FEYZA S ROBERTS, ELISABETH HELEN BURAK, MEHMET F DOYLE, CARL BRENDAN TYSON, KERRY LOUISE MOORE, ADRIAN RICHARD HERVE, KARINE JEANNINE MADELEINE HOTAMISLIGIL, GOKHAN S |
| description | This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as "aP2") for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_TW201702271A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>TW201702271A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_TW201702271A3</originalsourceid><addsrcrecordid>eNqNikEKwjAQAHPxIOof1gcU2njoOYgiePFQ8Fg2zVoW6qZk9_8YxAd4mhmYrbsHMW7CwwNWiTkxadX0zZkEIktimQFrmIJlsEJo8CbDmBeeILHmkqjo3m1euCgdfty54_UynG8NrXkkXXEiIRuHp2-7vvW-78Lpn-cDAz41CA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Anti-AP2 antibodies and antigen binding agents to treat metabolic disorders</title><source>esp@cenet</source><creator>WIDENMAIER, SCOTT B ; WALES, SHAUNA MHAIRI ; ADAMS, RALPH ; ENGIN, FEYZA S ; ROBERTS, ELISABETH HELEN ; BURAK, MEHMET F ; DOYLE, CARL BRENDAN ; TYSON, KERRY LOUISE ; MOORE, ADRIAN RICHARD ; HERVE, KARINE JEANNINE MADELEINE ; HOTAMISLIGIL, GOKHAN S</creator><creatorcontrib>WIDENMAIER, SCOTT B ; WALES, SHAUNA MHAIRI ; ADAMS, RALPH ; ENGIN, FEYZA S ; ROBERTS, ELISABETH HELEN ; BURAK, MEHMET F ; DOYLE, CARL BRENDAN ; TYSON, KERRY LOUISE ; MOORE, ADRIAN RICHARD ; HERVE, KARINE JEANNINE MADELEINE ; HOTAMISLIGIL, GOKHAN S</creatorcontrib><description>This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as "aP2") for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.</description><language>chi ; eng</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2017</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170116&DB=EPODOC&CC=TW&NR=201702271A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25563,76318</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170116&DB=EPODOC&CC=TW&NR=201702271A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>WIDENMAIER, SCOTT B</creatorcontrib><creatorcontrib>WALES, SHAUNA MHAIRI</creatorcontrib><creatorcontrib>ADAMS, RALPH</creatorcontrib><creatorcontrib>ENGIN, FEYZA S</creatorcontrib><creatorcontrib>ROBERTS, ELISABETH HELEN</creatorcontrib><creatorcontrib>BURAK, MEHMET F</creatorcontrib><creatorcontrib>DOYLE, CARL BRENDAN</creatorcontrib><creatorcontrib>TYSON, KERRY LOUISE</creatorcontrib><creatorcontrib>MOORE, ADRIAN RICHARD</creatorcontrib><creatorcontrib>HERVE, KARINE JEANNINE MADELEINE</creatorcontrib><creatorcontrib>HOTAMISLIGIL, GOKHAN S</creatorcontrib><title>Anti-AP2 antibodies and antigen binding agents to treat metabolic disorders</title><description>This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as "aP2") for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2017</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNikEKwjAQAHPxIOof1gcU2njoOYgiePFQ8Fg2zVoW6qZk9_8YxAd4mhmYrbsHMW7CwwNWiTkxadX0zZkEIktimQFrmIJlsEJo8CbDmBeeILHmkqjo3m1euCgdfty54_UynG8NrXkkXXEiIRuHp2-7vvW-78Lpn-cDAz41CA</recordid><startdate>20170116</startdate><enddate>20170116</enddate><creator>WIDENMAIER, SCOTT B</creator><creator>WALES, SHAUNA MHAIRI</creator><creator>ADAMS, RALPH</creator><creator>ENGIN, FEYZA S</creator><creator>ROBERTS, ELISABETH HELEN</creator><creator>BURAK, MEHMET F</creator><creator>DOYLE, CARL BRENDAN</creator><creator>TYSON, KERRY LOUISE</creator><creator>MOORE, ADRIAN RICHARD</creator><creator>HERVE, KARINE JEANNINE MADELEINE</creator><creator>HOTAMISLIGIL, GOKHAN S</creator><scope>EVB</scope></search><sort><creationdate>20170116</creationdate><title>Anti-AP2 antibodies and antigen binding agents to treat metabolic disorders</title><author>WIDENMAIER, SCOTT B ; WALES, SHAUNA MHAIRI ; ADAMS, RALPH ; ENGIN, FEYZA S ; ROBERTS, ELISABETH HELEN ; BURAK, MEHMET F ; DOYLE, CARL BRENDAN ; TYSON, KERRY LOUISE ; MOORE, ADRIAN RICHARD ; HERVE, KARINE JEANNINE MADELEINE ; HOTAMISLIGIL, GOKHAN S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_TW201702271A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2017</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>WIDENMAIER, SCOTT B</creatorcontrib><creatorcontrib>WALES, SHAUNA MHAIRI</creatorcontrib><creatorcontrib>ADAMS, RALPH</creatorcontrib><creatorcontrib>ENGIN, FEYZA S</creatorcontrib><creatorcontrib>ROBERTS, ELISABETH HELEN</creatorcontrib><creatorcontrib>BURAK, MEHMET F</creatorcontrib><creatorcontrib>DOYLE, CARL BRENDAN</creatorcontrib><creatorcontrib>TYSON, KERRY LOUISE</creatorcontrib><creatorcontrib>MOORE, ADRIAN RICHARD</creatorcontrib><creatorcontrib>HERVE, KARINE JEANNINE MADELEINE</creatorcontrib><creatorcontrib>HOTAMISLIGIL, GOKHAN S</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>WIDENMAIER, SCOTT B</au><au>WALES, SHAUNA MHAIRI</au><au>ADAMS, RALPH</au><au>ENGIN, FEYZA S</au><au>ROBERTS, ELISABETH HELEN</au><au>BURAK, MEHMET F</au><au>DOYLE, CARL BRENDAN</au><au>TYSON, KERRY LOUISE</au><au>MOORE, ADRIAN RICHARD</au><au>HERVE, KARINE JEANNINE MADELEINE</au><au>HOTAMISLIGIL, GOKHAN S</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Anti-AP2 antibodies and antigen binding agents to treat metabolic disorders</title><date>2017-01-16</date><risdate>2017</risdate><abstract>This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as "aP2") for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi ; eng |
| recordid | cdi_epo_espacenet_TW201702271A |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | Anti-AP2 antibodies and antigen binding agents to treat metabolic disorders |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T11%3A44%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=WIDENMAIER,%20SCOTT%20B&rft.date=2017-01-16&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ETW201702271A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |